Hjalmar Flygt
Research physician at Department of Medical Sciences; Haematology
- Telephone:
- +46 18 611 35 06
- E-mail:
- hjalmar.flygt@medsci.uu.se
- Visiting address:
- Akademiska sjukhuset, ing 101, plan 4
751 85 Uppsala - Postal address:
- Akademiska sjukhuset, ing 100, plan 2
751 85 Uppsala
Download contact information for Hjalmar Flygt at Department of Medical Sciences; Haematology
Publications
Recent publications
-
Part of Leukemia, p. 781-787, 2024
- DOI for Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial
- Download full text (pdf) of Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial
-
Clinical and Genetic studies in Chronic Myeloid Leukaemia
2024
-
Part of Leukemia, p. 1156-1159, 2023
- DOI for The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study
- Download full text (pdf) of The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study
-
Part of American Journal of Hematology, p. 421-430, 2022
- DOI for Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
- Download full text (pdf) of Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
-
Part of British Journal of Haematology, p. 915-921, 2021
- DOI for Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
- Download full text (pdf) of Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
All publications
Articles in journal
-
Part of Leukemia, p. 781-787, 2024
- DOI for Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial
- Download full text (pdf) of Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial
-
Part of Leukemia, p. 1156-1159, 2023
- DOI for The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study
- Download full text (pdf) of The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study
-
Part of American Journal of Hematology, p. 421-430, 2022
- DOI for Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
- Download full text (pdf) of Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
-
Part of British Journal of Haematology, p. 915-921, 2021
- DOI for Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
- Download full text (pdf) of Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
-
Part of European Journal of Haematology, p. 617-623, 2021
- DOI for Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study
- Download full text (pdf) of Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study